Total Payments
$94,305
2023 Payments
$12,050
Companies
7
Transactions
71
Payment Breakdown by Category
Consulting$66,899 (70.9%)
Research$19,704 (20.9%)
Other$2,866 (3.0%)
Food & Beverage$2,547 (2.7%)
Travel$2,289 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $66,899 | 22 | 70.9% |
| Unspecified | $19,704 | 9 | 20.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,866 | 1 | 3.0% |
| Food and Beverage | $2,547 | 31 | 2.7% |
| Travel and Lodging | $2,289 | 8 | 2.4% |
Payments by Type
General
$74,601
62 transactions
Research
$19,704
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $68,186 | 55 | $0 (2020) |
| CTI BioPharma Corp. | $12,050 | 1 | $0 (2023) |
| Jazz Pharmaceuticals Inc. | $7,264 | 8 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $4,814 | 2 | $0 (2021) |
| Rigel Pharmaceuticals, Inc. | $1,400 | 1 | $0 (2019) |
| Pacira Pharmaceuticals Incorporated | $383.00 | 1 | $0 (2017) |
| Stemline Therapeutics Inc. | $207.48 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $12,050 | 1 | CTI BioPharma Corp. ($12,050) |
| 2021 | $4,716 | 1 | Novartis Pharmaceuticals Corporation ($4,716) |
| 2020 | $6,654 | 5 | Celgene Corporation ($6,605) |
| 2019 | $37,007 | 28 | Celgene Corporation ($35,448) |
| 2018 | $19,412 | 18 | Celgene Corporation ($19,037) |
| 2017 | $14,465 | 18 | Celgene Corporation ($7,095) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Consulting Fee | Cash or cash equivalent | $12,050.00 | General |
| Category: Hematology | ||||||
| 03/27/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $4,716.00 | General |
| 01/30/2020 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 01/30/2020 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $307.43 | General |
| 01/30/2020 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $47.79 | General |
| 01/17/2020 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $49.18 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2020 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 12/13/2019 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 12/11/2019 | Celgene Corporation | Reblozyl (Drug) | Food and Beverage | In-kind items and services | $140.13 | General |
| Category: Beta Thalassemia | ||||||
| 12/08/2019 | Celgene Corporation | Reblozyl (Drug) | — | In-kind items and services | $3,223.00 | Research |
| Study: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) • Category: Beta Thalassemia | ||||||
| 12/07/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $96.20 | General |
| 12/07/2019 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $74.44 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | Celgene Corporation | Reblozyl (Drug) | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: Beta Thalassemia | ||||||
| 12/05/2019 | Celgene Corporation | Reblozyl (Drug) | Food and Beverage | In-kind items and services | $57.93 | General |
| Category: Beta Thalassemia | ||||||
| 12/04/2019 | Celgene Corporation | Reblozyl (Drug) | Food and Beverage | In-kind items and services | $52.73 | General |
| Category: Beta Thalassemia | ||||||
| 11/26/2019 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $8,250.00 | General |
| 10/28/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $76.63 | General |
| 10/16/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $125.79 | General |
| 10/16/2019 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $83.86 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2019 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 06/10/2019 | Celgene Corporation | Reblozyl (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Beta Thalassemia | ||||||
| 05/08/2019 | Celgene Corporation | Luspatercept (Drug) | — | In-kind items and services | $4,010.00 | Research |
| Study: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | ||||||
| 04/12/2019 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,866.00 | General |
| Category: Hematology / Oncology | ||||||
| 04/08/2019 | Celgene Corporation | — | Travel and Lodging | In-kind items and services | $386.67 | General |
| 04/08/2019 | Celgene Corporation | Luspatercept (Drug) | Food and Beverage | In-kind items and services | $144.55 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $7,233 | 2 |
| A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (AG-221-AML-004) | Celgene Corporation | $3,750 | 1 |
| AG-221-AML-004 | Celgene Corporation | $3,750 | 1 |
| ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $1,409 | 1 |
| AG-221-AML-004 - A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia H | Celgene Corporation | $1,250 | 1 |
| ACE-011-MDS-001 | Celgene Corporation | $1,156 | 1 |
| ACE-011-MF-PI-0005 | Celgene Corporation | $578.00 | 1 |
| CC-5013-MDS-003 - A Multicenter, Single-Arm, Open-Label Study of The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-Dependent Subjects with Myelodysplastic Syndromes Associated with a Del | Celgene Corporation | $578.00 | 1 |
About Dr. Alan List, MD
Dr. Alan List, MD is a Hematology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710908314.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan List, MD has received a total of $94,305 in payments from pharmaceutical and medical device companies, with $12,050 received in 2023. These payments were reported across 71 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($66,899).
Ad
Practice Information
- Specialty Hematology
- Location Tampa, FL
- Active Since 07/21/2006
- Last Updated 01/24/2008
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1710908314
Products in Payments
- Luspatercept (Drug) $17,276
- Vonjo (Drug) $12,050
- Idhifa (Drug) $11,829
- Reblozyl (Drug) $4,256
- Revlimid (Drug) $3,560
- Sotatercept (Drug) $1,734
- AML - Acute myeloid leukemia (Drug) $1,400
- EXPAREL (Drug) $383.00
- VYXEOS (Drug) $375.00
- ELZONRIS (Drug) $207.48
- KYMRIAH (Biological) $98.22
- Vidaza (Drug) $47.82
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Tampa
Rami Komrokji, M.d, M.D
Hematology — Payments: $850,782
Hematology $850,782
Dr. Julia Cogburn, M.d, M.D
Hematology — Payments: $133,076
Hematology $133,076
Dr. Robert Weaver, Md, MD
Hematology — Payments: $110,649
Hematology $110,649
Dr. David Wright, Md, MD
Hematology — Payments: $82,377
Hematology $82,377
Lubomir Sokol, Md, MD
Hematology — Payments: $27,903
Hematology $27,903
Dr. Hafeez Chatoor, M.d, M.D
Hematology — Payments: $27,426
Hematology $27,426